{"pmid":32423324,"title":"Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.","text":["Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.","Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience.","J Oncol Pharm Pract","Yekeduz, Emre","Dursun, Bengu","Aydin, Gule C","Yazgan, Sati C","Ozturk, Halis H","Azap, Alpay","Utkan, Gungor","Urun, Yuksel","32423324"],"abstract":["Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience."],"journal":"J Oncol Pharm Pract","authors":["Yekeduz, Emre","Dursun, Bengu","Aydin, Gule C","Yazgan, Sati C","Ozturk, Halis H","Azap, Alpay","Utkan, Gungor","Urun, Yuksel"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423324","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1078155220924084","keywords":["covid-19","sars-cov2","immunotherapy"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nivolumab","Hydroxychloroquine"],"topics":["Case Report"],"weight":1,"_version_":1667352728920129537,"score":9.490897,"similar":[{"pmid":32434789,"title":"Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","text":["Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic.","J Immunother Cancer","Serzan, Michael T","Kumar, Princy N","Atkins, Michael B","32434789"],"abstract":["BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic."],"journal":"J Immunother Cancer","authors":["Serzan, Michael T","Kumar, Princy N","Atkins, Michael B"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434789","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000898","keywords":["case reports","immunomodulation","immunotherapy","melanoma"],"e_drugs":["Steroids","Nivolumab","Ipilimumab"],"topics":["Treatment"],"weight":1,"_version_":1667521393798938624,"score":233.12115},{"pmid":32426877,"title":"Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.","text":["Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.","Melanoma epidemiology has shown a constant increase in the last few decades even if mortality is low and only a small percentage of patients develop metastatic disease. For these patients, immunotherapy with checkpoint inhibitors (ICI) significantly improves disease outcome with a median survival more than 2 years. The same drugs are used as adjuvant treatment in disease-free patients. Coronavirus Disease-19 (COVID-19) is now a pandemic disease with lung manifestations, which can bring severe acute respiratory distress. The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer).","J Eur Acad Dermatol Venereol","Quaglino, Pietro","Fava, Paolo","Brizio, Matteo","Marra, Elena","Rubatto, Marco","Agostini, Andrea","Tonella, Luca","Ribero, Simone","Fierro, Maria Teresa","32426877"],"abstract":["Melanoma epidemiology has shown a constant increase in the last few decades even if mortality is low and only a small percentage of patients develop metastatic disease. For these patients, immunotherapy with checkpoint inhibitors (ICI) significantly improves disease outcome with a median survival more than 2 years. The same drugs are used as adjuvant treatment in disease-free patients. Coronavirus Disease-19 (COVID-19) is now a pandemic disease with lung manifestations, which can bring severe acute respiratory distress. The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Quaglino, Pietro","Fava, Paolo","Brizio, Matteo","Marra, Elena","Rubatto, Marco","Agostini, Andrea","Tonella, Luca","Ribero, Simone","Fierro, Maria Teresa"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426877","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jdv.16586","locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1667252837773475841,"score":215.5356},{"pmid":32253068,"pmcid":"PMC7127009","title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","text":["Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.","J Autoimmun","Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo","32253068"],"abstract":["The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19."],"journal":"J Autoimmun","authors":["Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253068","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jaut.2020.102442","keywords":["antimalarials","baricitinib","covid-19","rheumatic diseases","sars-cov2","tocilizumab"],"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab","baricitinib"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493115432961,"score":204.45657},{"pmid":32502288,"title":"Melanoma defies 'lockdown': ongoing detection during Covid-19 in central London.","text":["Melanoma defies 'lockdown': ongoing detection during Covid-19 in central London.","The COVID-19 pandemic has presented significant challenges for Dermatology services, particularly the diagnosis and management of malignant melanoma (MM). Early detection and definitive surgical treatment are key to improving MM prognosis, and in England there is a suspected skin cancer referral pathway that facilitates specialist Dermatology assessment within two weeks. Here, we describe the impact of COVID-19 on MM detection, based on data from the a Dermatology Department in central London.","Clin Exp Dermatol","Schauer, A A","Kulakov, E L","Martyn-Simmons, C L","Bunker, C B","Edmonds, E","32502288"],"abstract":["The COVID-19 pandemic has presented significant challenges for Dermatology services, particularly the diagnosis and management of malignant melanoma (MM). Early detection and definitive surgical treatment are key to improving MM prognosis, and in England there is a suspected skin cancer referral pathway that facilitates specialist Dermatology assessment within two weeks. Here, we describe the impact of COVID-19 on MM detection, based on data from the a Dermatology Department in central London."],"journal":"Clin Exp Dermatol","authors":["Schauer, A A","Kulakov, E L","Martyn-Simmons, C L","Bunker, C B","Edmonds, E"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502288","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ced.14324","locations":["England","London","London"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1668804508718727169,"score":182.12251},{"pmid":32468229,"title":"Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt.","text":["Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt.","Melanoma is one of the most common cancers, with an increasing incidence worldwide. Disease stage represents the most important prognosis factor; therefore, early diagnosis is essential for melanoma patients' survival rates. Following the outbreak in China, the coronavirus disease 2019 (COVID-19) pandemic has spread all over the world and the majority of dermatological visits have been postponed. These measures could cause a delay in melanoma diagnosis and management leading to an increase of morbidity, mortality and healthcare costs. Herein we propose an alternative model of skin cancer screening and the organization of screening campaigns in order to detect malignant lesions early during this emergency period.","Dermatol Ther (Heidelb)","Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano","32468229"],"abstract":["Melanoma is one of the most common cancers, with an increasing incidence worldwide. Disease stage represents the most important prognosis factor; therefore, early diagnosis is essential for melanoma patients' survival rates. Following the outbreak in China, the coronavirus disease 2019 (COVID-19) pandemic has spread all over the world and the majority of dermatological visits have been postponed. These measures could cause a delay in melanoma diagnosis and management leading to an increase of morbidity, mortality and healthcare costs. Herein we propose an alternative model of skin cancer screening and the organization of screening campaigns in order to detect malignant lesions early during this emergency period."],"journal":"Dermatol Ther (Heidelb)","authors":["Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468229","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13555-020-00402-x","keywords":["dermatoscopy","early detection","melanoma","prevention","screening","skin cancer"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668167109951094785,"score":180.14586}]}